

WHAT IS CLAIMED IS:

[Claim 1]. A compound of the Formula ~~(I) or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof~~:



~~(I)~~



wherein ~~R^1 is selected from optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, optionally substituted aminylacylene, optionally substituted acylaminylene and optionally substituted acylene;~~

R^2 is selected from H, halogen, and optionally substituted C1-C6 alkyl~~methyl~~;

~~R^3 and R^4 are independently selected from H and methyl;~~


~~R_5~~R_6 is selected from H and C1-C6 alkyl~~methyl~~;

L is a~~n optionally substituted~~ linker selected from optionally substituted C2-C15 alkyl, and optionally substituted poly(ethoxy)~~having 2 to 18 atoms in the chain length;~~

~~X is a protein binding moiety~~; and

Z is N or CH.

[Claim 2]. The compound of any precedingaccording to claim 1, wherein R^2 is fluoro.



[Claim 3]. The compound ~~of any precedingaccording to~~ claim 1, ~~having the formula:~~

wherein R^6 is ~~H or C_1-C_6 alkyl, e.g.,~~ methyl~~;~~

~~X^1, X^2 and X^3 are independently selected from N and CH, and C-L^3, such that when X^1 and X^3 are N, X^2 is C-L^3; and~~

~~L^3 is a linker~~.


~~3. The compound of any preceding claim, wherein X^2 is N; and~~

~~X^1 and X^3 are CH.~~

4. The compound of any preceding claim, wherein X^2 is N; X^1 and X^3 are C-L^3 or CH; and the pyridyl moiety is attached at the 5-position of the oxindole ring.


5. The compound of any preceding claim, wherein X^2 is N; and X^1 is C-L^3.

6. The compound of any preceding claim, having the formula:




wherein L^4 is a linker; X^1, X^2 and X^3 are independently selected from N and CH, and C-L^4, such that when X^1 and X^3 are N, X^2 is C-L^4.

7. The compound of any preceding claim, having the formula:




wherein L^2 is a linker.

8. The compound of any preceding claim, having the formula:




wherein L^1 is a linker.


9. The compound of any preceding claim, wherein X is:



10. The compound of any preceding claim, wherein X is:




11. The compound of any preceding claim, having the formula:




in which L^2 is a linker.

12. The compound of any previous claim, having the formula:




in which L^1 is a linker.

13. The compound of any previous claim, having the formula:




~~in which L^5 is a linker.~~

~~14. The compound of any preceding claim, having the formula:~~




~~wherein L^5 is a linker.~~

~~15. The compound of any preceding claim, wherein R^1 is selected from:~~



and

~~16. The compound of any preceding claim, wherein the linker is a member selected from:~~



~~wherein the index m is an integer from 1 to 6; and the index n is an integer from 1 to 18.~~

~~17. The compound of any preceding claim, wherein R^1 is located at either a 5' or 6' position of the oxindole ring.~~

~~18. The compound of any preceding claim, wherein R^1 is selected from optionally substituted phenylene, optionally substituted pyridinylene, optionally substituted pyrazolylene, optionally substituted aminylacylene, optionally substituted acylaminylene.~~









~~19. The compound of any preceding claim, wherein the optional substituent at R^1 is selected from optionally substituted heterocyclyl, optionally substituted amino, optionally substituted aminoacyl, optionally substituted acylamino, optionally substituted aryl and optionally substituted heteroaryl.~~










[Claim ~~420~~]. The compound ~~of any preceding~~according to claim 1, wherein, ~~R^1 is optionally substituted heteroarylene and~~ R^2 is fluoro; and R^6 is ~~selected from H, halogen or~~ methyl.








[Claim 5]. The compound according to claim 4, wherein Z is N.








[Claim 6]. A compound of a formula selected from:








1







Compound ID	Structure
096	
097	
098	
099	
100	
101	
102	
103	








104	 ;
105	 ;
106	 ;
107	 ;
108	 ;
109	 ;
110	 ;
111	 ;
112	 ;








113	 ;
114	 ;
115	 ;
116	 ;
117	 ;
118	 ;
119	 ;









120	 ;
121	 ;
122	 ;
123	 ;
124	 ;
125	 ;
126	 ;









127	 ;
128	 ;
129	 ;
130	 ;
131	 ;
132	 ;
133	 ;


134	 ;
135	 ;
136	 ;
137	 ;
138	 ;
139	 ;

140	 ;
141	 ;
142	 ;
143	 ;
144	 ;
145	 ;
146	 ;

147	 ;
148	 ;
149	 ;
150	 ;
151	 ;
152	 ;
153	 ;

154	 ;
155	 ;
156	 ;
157	 ;
158	 ;
159	 ;
160	 ;
161	 ;

162	 ;
163	 ;
164	 ;
165	 ;
166	 ;
167	 ;
168	 ;
169	 ; and

170	

.

21. The compound of any preceding claim, wherein the linker is selected from optionally substituted alkylene, optionally substituted heteroalkylene and optionally substituted cycloalkylene.


22. The compound of any preceding claim, wherein the linker is selected from optionally substituted alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene and optionally substituted heterocyclylene, each having 2 to 18 atoms in the

chain length, and optionally substituted polyethoxy having 2 to 18 atoms in the chain length.

23. The compound of any preceding claim, wherein X is selected from bromodomain-containing protein 4 (BRD4) binding moiety, transcriptional enhanced associate domain (TEAD) binding moiety, Polycomb Repressive Complex 2 (PRC2) binding moiety, focal adhesion kinase (FAK) binding moiety, BCR-ABL binding moiety, Hippo pathway protein binding moiety and transcription factor binding moiety.

24. The compound according to any preceding claim, having a formula according to Table 1.

25. A compound of Formula (XI) or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof:




(XI)


wherein $R^{1'}$ is selected from optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aminoacyl, optionally substituted acylamino and optionally substituted acyl;
R^2 is selected from H, halogen and methyl;
R^3 and R^4 are independently selected from H and methyl; and
R^5 is selected from H and methyl; and
Z is selected from CH, and N,
wherein $R^{1'}$ is located at either a 5' or 6' position of the oxindole ring.

26. The compound of Formula (XI) according to 25,
wherein $R^{1'}$ is selected from optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrazolyl, optionally substituted indolyl, optionally substituted azaindolyl, optionally substituted aminoacyl, optionally substituted acylamino, optionally substituted heterocyclylacyl and optionally substituted piperidinyl.

27. The compound of Formula (XI) according to 25 or 26, as represented by Formula (XI') or (XII'):




(XI')




(XI'') .

28. The compound of Formula (II) according to any one of claims 25-27, as represented by Formulae (XI'a) or (XI''a):



(XI'a)




(XI''a)

wherein R^2, R^3, R^4 and R^5 are as defined herein, and

wherein R^6 is selected optionally substituted amino, optionally substituted aminoacyl and optionally substituted acylamino.

29. The compound of Formulae (XI'a) or (XI''a) according to any one of claims 25-28, wherein R^6 is optionally substituted spirocycloalkyl.

30. A compound of Formula (XII) or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof:



(XII)

wherein R_1, R_2, R_3, R_4 and R_5 are as defined herein;

wherein R_1 is located at either a 5' or 6' position of the oxindole ring; and

L is an optionally substituted linker having 2 to 18 atoms in the chain length.

31. A pharmaceutical composition comprising an effective amount of compound of a compound of any preceding claim or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof, optionally in combination with a pharmaceutically acceptable carrier, excipient or diluent.

32. A method of inducing degradation of an overexpressed protein in a cell, including a step of contacting a compound of any preceding claim with the cell to induce degradation of the overexpressed protein in the cell.

33. A method of treating a disease or condition associated with an overexpressed protein, comprising administering a compound of any preceding claim or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof in a patient in need thereof.

34. The method according to either of claims 32 or 33, wherein the overexpressed protein is selected from BRD4, transcriptional enhanced associate domain (TEAD), Polycomb Repressive Complex 2 (PRC2), focal adhesion kinase (FAK), BCR-ABL, Hippo pathway protein and transcription factor.

35. The method according to any one of claims 32-34, wherein the disease or condition is selected from hyperplasia and cancer (such as multiple myeloma, glioblastoma, uveal melanoma, liposarcoma, hepatocellular carcinoma, midline carcinoma, acute myeloid leukemia, Burkitt lymphoma and prostate cancer) and a protein accumulation disease (such as Alzheimer's disease and amyotrophic lateral sclerosis).

36. A compound of any of claims 1-30 or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof for use as a medicament.

37. A compound of any of claims 1-30 or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof for use in the treatment of a disease or condition associated with an overexpressed protein.

38. The compound according to either of claims 36 or 37, wherein the disease or

~~condition is selected from hyperplasia and cancer (such as multiple myeloma, glioblastoma, uveal melanoma, liposarcoma, hepatocellular carcinoma, midline carcinoma, acute myeloid leukemia, Burkitt lymphoma and prostate cancer) and a protein accumulation disease (such as Alzheimer's disease and amyotrophic lateral sclerosis).~~

~~39. Use of a compound of any of claims 1-30 or a pharmaceutically acceptable salt, solvate, stereoisomer or prodrug thereof in the manufacture of a medicament for the treatment of a disease or condition associated with an overexpressed protein.~~

~~40. The use according to claim 39, wherein the disease or condition is selected from hyperplasia, cancer (such as multiple myeloma, glioblastoma, uveal melanoma, liposarcoma, hepatocellular carcinoma, midline carcinoma, acute myeloid leukemia, Burkitt lymphoma and prostate cancer) and protein-accumulation disease (such as Alzheimer's disease and amyotrophic lateral sclerosis).~~

~~41. The ternary complex comprising a first protein and a second protein interacting with a first moiety and a second moiety, respectively, of the compound of any of claims 1-24~~